 |
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
Specialised Models
Leukemia Models
vivoPharm offers CML, CLL and AML models in SCID mice. Our studies are undertaken in animals selected for the presence of leukemia. Disease progression is used as the main monitoring parameter in combination with survival. With leukemia models vivoPharm has supported the progression of at least one compound into clinical trial.
Metastasis Osteoporosis Models
Bone is the third most common site of metastatic disease. Cancers most likely to metastasize to bone include breast, lung, prostate, thyroid and kidney. Until now, there has been a lack of in vivo models to test novel cancer therapies against bone metastases. Consequently, vivoPharm has developed specialist technology to produce a model mimicking the growth of several cancers in bone. Together with partners, we have optimised our analytical methods (including X-Ray and microCT systems) to correlate efficacy of therapy with changes in bone density. This improved protocol is also suitable for use with breast cancer and multiple myeloma.
Oncogene genetically modified models
A NeuT (ErbB2)-driven syngeneic orthotopic tumour model for testing efficacy of anti-cancer compounds has been specially designed to inhibit ErbB2 or EGFR. Tumours of this model are characterized by a morphology and response rate to therapy similar to that experienced in cancer patients. Therefore this model is believed to present a high clinical predictability
In brief, drug-selected NeuT infected mammary epithelial cell populations are introduced into mammary fat pads of BALB/c syngeneic mice which have been cleared of host tissue. Breast tumours develop within a 3 to 4 week latency period and grow rapidly. The histology of the breast tumours is comparable to those observed in MMTV-NeuT transgenic mice. Most importantly, this tumour model is to our knowledge the first oncogene-driven model with a heterogeneous therapy response within a treatment group.